At-Home Heart Failure Edema Treatment Shows Positive Results in SUBCUT HF II Trial
BURLINGTON: SQ Innovation has announced positive results from the SUBCUT HF II trial, showing that at-home treatment for heart failure-related edema using Lasix ONYU can serve as a safe and effective alternative to hospital care.
The findings were presented during the Heart Failure 2026 congress organised by the European Society of Cardiology in Barcelona, Spain.
According to the company, patients treated at home with the subcutaneous furosemide formulation spent an average of four fewer days in hospital compared to those receiving standard intravenous (IV) therapy.
The SUBCUT HF II trial was conducted as a randomised study involving 20 National Health Service (NHS) hospitals across the United Kingdom.
The study was jointly organised by the University of Glasgow and the Greater Glasgow and Clyde Health Board under the leadership of cardiologists Ross T. Campbell and Mark C. Petrie.
Professor Petrie said heart failure-related edema remains one of the leading causes of hospital admissions worldwide and that the new treatment option could transform patient care approaches.
He explained that a therapy traditionally limited to hospitals can now be safely and conveniently administered at home by patients or caregivers.
The trial involved 172 heart failure patients suffering from fluid overload or edema following hospital admission.
Of the total participants, 92 patients received at-home treatment using Lasix ONYU while 80 underwent standard hospital-based IV diuretic treatment.
Participants had an average age of 71, with most experiencing peripheral edema while some also suffered from pleural effusion.
The main objective of the study was to evaluate the number of days patients remained alive and outside hospital during the 30-day period after treatment began.
Results showed that patients receiving at-home treatment spent four additional days outside hospital compared to those under standard care.
Hospital stays were also reduced by 5.5 days, with the treatment benefits continuing through the 60-day follow-up period.
Researchers further found that at-home Lasix ONYU treatment achieved effectiveness comparable to hospital treatment without increased safety risks.
Reported side effects were minimal and no serious device-related incidents were recorded during the trial.
SQ Innovation founder and chief executive officer Pieter Muntendam said the study marked a major milestone in efforts to bring heart failure treatment directly into patients’ homes.
He added that the approach could help reduce hospital overcrowding while improving comfort for elderly patients requiring ongoing treatment.
Lasix ONYU previously received approval from the Food and Drug Administration (FDA) in October 2025 for treating edema in adults with chronic heart failure.
-wilayah.com.my
